Global Non-Alcoholic Steatohepatitis Diagnostics Market By Offerings (Diagnostic Assays, Others); By Diagnosis (Serum Biomarkers, Liver Biopsy and Liver enzyme testing, Echography, Histological Assessment of Liver Tissue, Physical Examination, Blood Tests, Imaging Tests – Magnetic Resonance Imaging (MRI), Ultrasound, Others, Others); By Patient Type (Adult, Pediatric); By End User (Hospitals and Clinics, Research & Academic Institutes, Diagnostics, Pharma Companies, Others); By Region (U.S., Canada, Mexico, Rest of North America, France, UK, Germany, Spain, Italy, Nordic Countries, Benelux Union, Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Rest of Asia Pacific, Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of MEA, Brazil, Argentina, Rest of Latin America) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2022 – 2030

Report ID :AMI-1310 | Category : Healthcare | Published Date : November, 2022 | Pages : 402 | Format :PDF

Industry Trends

In terms of revenue, the global non-alcoholic steatohepatitis diagnostics market is growing at an estimated CAGR of 34% over the forecast period. Non-alcoholic steatohepatitis basically is a liver disease. In this disease, fat builds up in the one’s liver, who hasn’t drink anything or drinks in moderation sometimes. Non-alcoholic steatohepatitis causes the liver to inflame and causes damage to the cells in the liver, and this is likely to turn into liver cirrhosis and also liver failure. People who are suffering from nonalcoholic steatohepatitis are more prone to suffer from liver cancer. This disease is more commonly seen adults of middle age, specifically in those who happen to be overweight or obese or are suffering from chronic diseases like diabetes or high levels of cholesterol and triglycerides. There are numerous factors like sedentary lifestyle and changing work culture that are causing diseases like non-alcoholic steatohepatitis. Meanwhile, diagnosis of utmost importance and first step towards treating any type disease. The non-alcoholic steatohepatitis diagnostics market is aggressively growing courtesy of various factors.

Meanwhile, the coronavirus pandemic proved helpful for the growth of the non-alcoholic steatohepatitis diagnostics market. People with non-fatty liver were more under the risk of being infected from a dreadful virus first found in China. This is why more diagnostic services were sought.

Offerings Outlook

On the basis of offerings, the non-alcoholic steatohepatitis diagnostics market has been divided into diagnostics assays and others. The diagnostic assays segment accounts for majority of revenue generated by this market. Diagnostic assays happen to be laboratory test to determine and measure the amount of a particular substance. It plays crucial role in the process of diagnostic a disease.

Diagnosis Outlook

On the basis of diagnosis, the non-alcoholic steatohepatitis diagnostics market has been categorised into serum biomarkers, liver biopsy and liver enzyme testing, echography, histological assessment of liver tissue, physical examination, blood tests, imaging tests and others. The imaging tests segment was further bifurcated into magnetic resonance imaging (MRI), ultrasound and others. Liver biopsy and liver enzyme testing segment has dominating in terms of market share, as it helps determine the amount of damage done to the liver.

Global Non-Alcoholic Steatohepatitis Diagnostics Market Revenue & Forecast, (US$ Million), 2022 – 2030

Global Non-Alcoholic Steatohepatitis Diagnostics Market

 Patient Type Outlook

The patient type segment of the non-alcoholic steatohepatitis diagnostics market has been segmented into adult and pediatric. The adult segment mints maximum amount for this market. This ailment is suffered majorly by those suffering from obesity or even are slightly overweight. Also the fact that people suffering chronic diseases like diabetes belong to adult age group. This is exactly why this segment dominates.

End User Outlook

The end user segment of the non-alcoholic steatohepatitis diagnostics market has been bifurcated into hospitals and clinics, research & academic institutes, diagnostics, pharma companies and others. The hospitals and clinics segment accounts for major chunk of money minted by this market. Number of people opting to get themselves treated in hospitals and clinics are more, and this is why these institutes are using latest diagnostics machines.

Region Outlook 

On the basis of region, the non-alcoholic steatohepatitis diagnostics market has been divided into Latin America, Europe, North America, Asia-Pacific and others. The region of the North America accounts for most of the money for this market. Availability of better medical infrastructure along with high awareness about various diseases helps this market grow in the region.

Competitive Landscape 

The report provides both, qualitative and quantitative research of global non-alcoholic steatohepatitis diagnostics market as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contacts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.

Some of the major players operating in the global non-alcoholic steatohepatitis diagnostics market are listed below:

  • Galmed
  • Genfit
  • Intercept
  • Other Market Participants

Global Non-Alcoholic Steatohepatitis Diagnostics Market 

By Offerings 

  • Diagnostic Assays
  • Others

By Diagnosis 

  • Serum Biomarkers
  • Liver Biopsy and liver enzyme testing
  • Echography
  • Histological assessment of liver tissue
  • Physical Examination
  • Blood Tests
  • Imaging Tests
  • Magnetic resonance imaging (MRI)
    • Ultrasound
    • Others
  • Others

By Patient Type 

  • Adult Type
  • Pediatric

By End-User 

  • Hospitals and Clinics
  • Research & Academic Institutes
  • Diagnostics
  • Pharma Companies
  • Others

By Region

  • North America
    • U.S
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Nordic Countries
      • Denmark
      • Finland
      • Iceland
      • Sweden
      • Norway
    • Benelux Union
      • Belgium
      • The Netherlands
      • Luxembourg
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • New Zealand
    • Australia
    • South Korea
    • Southeast Asia
      • Indonesia
      • Thailand
      • Malaysia
      • Singapore
      • Rest of Southeast Asia
    • Rest of Asia Pacific
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Egypt
    • Kuwait
    • South Africa
    • Rest of Middle East & Africa
  • Latin America
    • Brazil
    • Argentina
    • Rest of Latin America 

Table of Contents

1.    Market Scope

1.1.   Market Segmentation

1.2.   Years Considered

1.2.1.   Historic Year: 2020

1.2.2.   Base Year: 2021

1.2.3.   Forecast Years: 2022 – 2030

2.    Key Target Audiences

3.    Research Methodology

3.1.   Primary Research

3.1.1.   Research Questionnaire

3.1.2.   Global Percentage Breakdown

3.1.3.   Primary Interviews: Key Opinion Leaders (KOLs)

3.2.   Secondary Research

3.2.1.   Paid Databases

3.2.2.   Secondary Sources

3.3.   Market Size Estimates

3.3.1.   Top-Down Approach

3.3.2.   Bottom-Up Approach

3.4.   Data Triangulation Methodology

3.5.   Research Assumptions

4.    Recommendations and Insights from AMI’s Perspective**

5.    Holistic Overview of Non-Alcoholic Steatohepatitis Diagnostics Market

6.    Market Synopsis:  Non-Alcoholic Steatohepatitis Diagnostics Market

7.    Non-Alcoholic Steatohepatitis Diagnostics Market Analysis: Qualitative Perspective

7.1.   Introduction

7.1.1.   Product Definition

7.1.2.   Industry Development

7.2.   Market Dynamics

7.2.1.   Drivers

7.2.2.   Restraints

7.2.3.   Opportunities

7.2.4.   Challenges

7.3.   Trends in Non-Alcoholic Steatohepatitis Diagnostics Market

7.4.   Market Determinants Radar Chart

7.5.   Macro-Economic and Micro-Economic Indicators: Non-Alcoholic Steatohepatitis Diagnostics Market

7.6.   Porter’s Five Force Analysis

7.7.   Impact of Covid-19 on Non-Alcoholic Steatohepatitis Diagnostics Market

8.    Global Non-Alcoholic Steatohepatitis Diagnostics Market Analysis and Forecasts, 2022 – 2030

8.1.   Overview

8.1.1.   Global Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn)

8.2.   Global Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings

8.2.1.   Diagnostic Assays

8.2.1.1.    Definition

8.2.1.2.    Market Estimation and Penetration, 2020 - 2021

8.2.1.3.    Market Forecast, 2022 - 2030

8.2.1.4.    Compound Annual Growth Rate (CAGR)

8.2.1.5.    Regional Bifurcation

8.2.1.5.1.    North America

8.2.1.5.1.1. Market Estimation, 2020 - 2021

8.2.1.5.1.2. Market Forecast, 2022 - 2030

8.2.1.5.2.    Europe

8.2.1.5.2.1. Market Estimation, 2020 - 2021

8.2.1.5.2.2. Market Forecast, 2022 - 2030

8.2.1.5.3.    Asia Pacific

8.2.1.5.3.1. Market Estimation, 2020 - 2021

8.2.1.5.3.2. Market Forecast, 2022 - 2030

8.2.1.5.4.    Middle East and Africa

8.2.1.5.4.1. Market Estimation, 2020 - 2021

8.2.1.5.4.2. Market Forecast, 2022 - 2030

8.2.1.5.5.    Latin America

8.2.1.5.5.1. Market Estimation, 2020 - 2021

8.2.1.5.5.2. Market Forecast, 2022 - 2030

8.2.2.    Others

8.2.2.1.    Definition

8.2.2.2.    Market Estimation and Penetration, 2020 - 2021

8.2.2.3.    Market Forecast, 2022 - 2030

8.2.2.4.    Compound Annual Growth Rate (CAGR)

8.2.2.5.    Regional Bifurcation

8.2.2.5.1.    North America

8.2.2.5.1.1. Market Estimation, 2020 - 2021

8.2.2.5.1.2. Market Forecast, 2022 - 2030

8.2.2.5.2.    Europe

8.2.2.5.2.1. Market Estimation, 2020 - 2021

8.2.2.5.2.2. Market Forecast, 2022 - 2030

8.2.2.5.3.    Asia Pacific

8.2.2.5.3.1. Market Estimation, 2020 - 2021

8.2.2.5.3.2. Market Forecast, 2022 - 2030

8.2.2.5.4.    Middle East and Africa

8.2.2.5.4.1. Market Estimation, 2020 - 2021

8.2.2.5.4.2. Market Forecast, 2022 - 2030

8.2.2.5.5.    Latin America

8.2.2.5.5.1. Market Estimation, 2020 - 2021

8.2.2.5.5.2. Market Forecast, 2022 - 2030

8.3.   Key Segment for Channeling Investments

8.3.1.   By Offerings

9.    Global Non-Alcoholic Steatohepatitis Diagnostics Market Analysis and Forecasts, 2022 – 2030

9.1.   Overview

9.2.   Global Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Diagnosis

9.2.1.   Serum Biomarkers

9.2.1.1.    Definition

9.2.1.2.    Market Estimation and Penetration, 2020 - 2021

9.2.1.3.    Market Forecast, 2022 - 2030

9.2.1.4.    Compound Annual Growth Rate (CAGR)

9.2.1.5.    Regional Bifurcation

9.2.1.5.1.    North America

9.2.1.5.1.1. Market Estimation, 2020 - 2021

9.2.1.5.1.2. Market Forecast, 2022 - 2030

9.2.1.5.2.    Europe

9.2.1.5.2.1. Market Estimation, 2020 - 2021

9.2.1.5.2.2. Market Forecast, 2022 - 2030

9.2.1.5.3.    Asia Pacific

9.2.1.5.3.1. Market Estimation, 2020 - 2021

9.2.1.5.3.2. Market Forecast, 2022 - 2030

9.2.1.5.4.    Middle East and Africa

9.2.1.5.4.1. Market Estimation, 2020 - 2021

9.2.1.5.4.2. Market Forecast, 2022 - 2030

9.2.1.5.5.    Latin America

9.2.1.5.5.1. Market Estimation, 2020 - 2021

9.2.1.5.5.2. Market Forecast, 2022 - 2030

9.2.2.   Liver Biopsy and liver enzyme testing

9.2.2.1.    Definition

9.2.2.2.    Market Estimation and Penetration, 2020 - 2021

9.2.2.3.    Market Forecast, 2022 - 2030

9.2.2.4.    Compound Annual Growth Rate (CAGR)

9.2.2.5.    Regional Bifurcation

9.2.2.5.1.    North America

9.2.2.5.1.1. Market Estimation, 2020 - 2021

9.2.2.5.1.2. Market Forecast, 2022 - 2030

9.2.2.5.2.    Europe

9.2.2.5.2.1. Market Estimation, 2020 - 2021

9.2.2.5.2.2. Market Forecast, 2022 - 2030

9.2.2.5.3.    Asia Pacific

9.2.2.5.3.1. Market Estimation, 2020 - 2021

9.2.2.5.3.2. Market Forecast, 2022 - 2030

9.2.2.5.4.    Middle East and Africa

9.2.2.5.4.1. Market Estimation, 2020 - 2021

9.2.2.5.4.2. Market Forecast, 2022 - 2030

9.2.2.5.5.    Latin America

9.2.2.5.5.1. Market Estimation, 2020 - 2021

9.2.2.5.5.2. Market Forecast, 2022 - 2030

9.2.3.   Echography

9.2.3.1.    Definition

9.2.3.2.    Market Estimation and Penetration, 2020 - 2021

9.2.3.3.    Market Forecast, 2022 - 2030

9.2.3.4.    Compound Annual Growth Rate (CAGR)

9.2.3.5.    Regional Bifurcation

9.2.3.5.1.    North America

9.2.3.5.1.1. Market Estimation, 2020 - 2021

9.2.3.5.1.2. Market Forecast, 2022 - 2030

9.2.3.5.2.    Europe

9.2.3.5.2.1. Market Estimation, 2020 - 2021

9.2.3.5.2.2. Market Forecast, 2022 - 2030

9.2.3.5.3.    Asia Pacific

9.2.3.5.3.1. Market Estimation, 2020 - 2021

9.2.3.5.3.2. Market Forecast, 2022 - 2030

9.2.3.5.4.    Middle East and Africa

9.2.3.5.4.1. Market Estimation, 2020 - 2021

9.2.3.5.4.2. Market Forecast, 2022 - 2030

9.2.3.5.5.    Latin America

9.2.3.5.5.1. Market Estimation, 2020 - 2021

9.2.3.5.5.2. Market Forecast, 2022 - 2030

9.2.4.   Histological assessment of liver tissue

9.2.4.1.    Definition

9.2.4.2.    Market Estimation and Penetration, 2020 - 2021

9.2.4.3.    Market Forecast, 2022 - 2030

9.2.4.4.    Compound Annual Growth Rate (CAGR)

9.2.4.5.    Regional Bifurcation

9.2.4.5.1.    North America

9.2.4.5.1.1. Market Estimation, 2020 - 2021

9.2.4.5.1.2. Market Forecast, 2022 - 2030

9.2.4.5.2.    Europe

9.2.4.5.2.1. Market Estimation, 2020 - 2021

9.2.4.5.2.2. Market Forecast, 2022 - 2030

9.2.4.5.3.    Asia Pacific

9.2.4.5.3.1. Market Estimation, 2020 - 2021

9.2.4.5.3.2. Market Forecast, 2022 - 2030

9.2.4.5.4.    Middle East and Africa

9.2.4.5.4.1. Market Estimation, 2020 - 2021

9.2.4.5.4.2. Market Forecast, 2022 - 2030

9.2.4.5.5.    Latin America

9.2.4.5.5.1. Market Estimation, 2020 - 2021

9.2.4.5.5.2. Market Forecast, 2022 - 2030

9.2.5.   Physical Examination

9.2.5.1.    Definition

9.2.5.2.    Market Estimation and Penetration, 2020 - 2021

9.2.5.3.    Market Forecast, 2022 - 2030

9.2.5.4.    Compound Annual Growth Rate (CAGR)

9.2.5.5.    Regional Bifurcation

9.2.5.5.1.    North America

9.2.5.5.1.1. Market Estimation, 2020 - 2021

9.2.5.5.1.2. Market Forecast, 2022 - 2030

9.2.5.5.2.    Europe

9.2.5.5.2.1. Market Estimation, 2020 - 2021

9.2.5.5.2.2. Market Forecast, 2022 - 2030

9.2.5.5.3.    Asia Pacific

9.2.5.5.3.1. Market Estimation, 2020 - 2021

9.2.5.5.3.2. Market Forecast, 2022 - 2030

9.2.5.5.4.    Middle East and Africa

9.2.5.5.4.1. Market Estimation, 2020 - 2021

9.2.5.5.4.2. Market Forecast, 2022 - 2030

9.2.5.5.5.    Latin America

9.2.5.5.5.1. Market Estimation, 2020 - 2021

9.2.5.5.5.2. Market Forecast, 2022 - 2030

9.2.6.   Blood Tests

9.2.6.1.    Definition

9.2.6.2.    Market Estimation and Penetration, 2020 - 2021

9.2.6.3.    Market Forecast, 2022 - 2030

9.2.6.4.    Compound Annual Growth Rate (CAGR)

9.2.6.5.    Regional Bifurcation

9.2.6.5.1.    North America

9.2.6.5.1.1. Market Estimation, 2020 - 2021

9.2.6.5.1.2. Market Forecast, 2022 - 2030

9.2.6.5.2.    Europe

9.2.6.5.2.1. Market Estimation, 2020 - 2021

9.2.6.5.2.2. Market Forecast, 2022 - 2030

9.2.6.5.3.    Asia Pacific

9.2.6.5.3.1. Market Estimation, 2020 - 2021

9.2.6.5.3.2. Market Forecast, 2022 - 2030

9.2.6.5.4.    Middle East and Africa

9.2.6.5.4.1. Market Estimation, 2020 - 2021

9.2.6.5.4.2. Market Forecast, 2022 - 2030

9.2.6.5.5.    Latin America

9.2.6.5.5.1. Market Estimation, 2020 - 2021

9.2.6.5.5.2. Market Forecast, 2022 - 2030

9.2.7.   Imaging Tests

9.2.7.1.    Definition

9.2.7.2.    Market Estimation and Penetration, 2020 - 2021

9.2.7.3.    Market Forecast, 2022 - 2030

9.2.7.4.    Compound Annual Growth Rate (CAGR)

9.2.7.5.    Regional Bifurcation

9.2.7.5.1.    North America

9.2.7.5.1.1. Market Estimation, 2020 - 2021

9.2.7.5.1.2. Market Forecast, 2022 - 2030

9.2.7.5.2.    Europe

9.2.7.5.2.1. Market Estimation, 2020 - 2021

9.2.7.5.2.2. Market Forecast, 2022 - 2030

9.2.7.5.3.    Asia Pacific

9.2.7.5.3.1. Market Estimation, 2020 - 2021

9.2.7.5.3.2. Market Forecast, 2022 - 2030

9.2.7.5.4.    Middle East and Africa

9.2.7.5.4.1. Market Estimation, 2020 - 2021

9.2.7.5.4.2. Market Forecast, 2022 - 2030

9.2.7.5.5.    Latin America

9.2.7.5.5.1. Market Estimation, 2020 - 2021

9.2.7.5.5.2. Market Forecast, 2022 - 2030

9.2.8.   Magnetic resonance imaging (MRI) (Definition, Market Estimation and Penetration, 2020 - 2021, Market Estimation (2020 - 2021), Market Forecast (2022 - 2030), Compound Annual Growth Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East and Africa, Latin America) and Information on Ultrasound, Others)

9.2.8.1.    Ultrasound

9.2.8.2.    Others

9.2.9.   Others

9.2.9.1.    Definition

9.2.9.2.    Market Estimation and Penetration, 2020 - 2021

9.2.9.3.    Market Forecast, 2022 - 2030

9.2.9.4.    Compound Annual Growth Rate (CAGR)

9.2.9.5.    Regional Bifurcation

9.2.9.5.1.    North America

9.2.9.5.1.1. Market Estimation, 2020 - 2021

9.2.9.5.1.2. Market Forecast, 2022 - 2030

9.2.9.5.2.    Europe

9.2.9.5.2.1. Market Estimation, 2020 - 2021

9.2.9.5.2.2. Market Forecast, 2022 - 2030

9.2.9.5.3.    Asia Pacific

9.2.9.5.3.1. Market Estimation, 2020 - 2021

9.2.9.5.3.2. Market Forecast, 2022 - 2030

9.2.9.5.4.    Middle East and Africa

9.2.9.5.4.1. Market Estimation, 2020 - 2021

9.2.9.5.4.2. Market Forecast, 2022 - 2030

9.2.9.5.5.    Latin America

9.2.9.5.5.1. Market Estimation, 2020 - 2021

9.2.9.5.5.2. Market Forecast, 2022 - 2030

9.3.   Key Segment for Channeling Investments

9.3.1.   By Diagnosis

10. Global Non-Alcoholic Steatohepatitis Diagnostics Market Analysis and Forecasts, 2022 – 2030

10.1. Overview

10.2. Global Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Patient Type

10.2.1. Adult

10.2.1.1.  Definition

10.2.1.2.  Market Estimation and Penetration, 2020 - 2021

10.2.1.3.  Market Forecast, 2022 - 2030

10.2.1.4.  Compound Annual Growth Rate (CAGR)

10.2.1.5.  Regional Bifurcation

10.2.1.5.1.  North America

10.2.1.5.1.1. Market Estimation, 2020 - 2021

10.2.1.5.1.2. Market Forecast, 2022 - 2030

10.2.1.5.2.  Europe

10.2.1.5.2.1. Market Estimation, 2020 - 2021

10.2.1.5.2.2. Market Forecast, 2022 - 2030

10.2.1.5.3.  Asia Pacific

10.2.1.5.3.1. Market Estimation, 2020 - 2021

10.2.1.5.3.2. Market Forecast, 2022 - 2030

10.2.1.5.4.  Middle East and Africa

10.2.1.5.4.1. Market Estimation, 2020 - 2021

10.2.1.5.4.2. Market Forecast, 2022 - 2030

10.2.1.5.5.  Latin America

10.2.1.5.5.1. Market Estimation, 2020 - 2021

10.2.1.5.5.2. Market Forecast, 2022 - 2030

10.2.2. Pediatric

10.2.2.1.  Definition

10.2.2.2.  Market Estimation and Penetration, 2020 - 2021

10.2.2.3.  Market Forecast, 2022 - 2030

10.2.2.4.  Compound Annual Growth Rate (CAGR)

10.2.2.5.  Regional Bifurcation

10.2.2.5.1.  North America

10.2.2.5.1.1. Market Estimation, 2020 - 2021

10.2.2.5.1.2. Market Forecast, 2022 - 2030

10.2.2.5.2.  Europe

10.2.2.5.2.1. Market Estimation, 2020 - 2021

10.2.2.5.2.2. Market Forecast, 2022 - 2030

10.2.2.5.3.  Asia Pacific

10.2.2.5.3.1. Market Estimation, 2020 - 2021

10.2.2.5.3.2. Market Forecast, 2022 - 2030

10.2.2.5.4.  Middle East and Africa

10.2.2.5.4.1. Market Estimation, 2020 - 2021

10.2.2.5.4.2. Market Forecast, 2022 - 2030

10.2.2.5.5.  Latin America

10.2.2.5.5.1. Market Estimation, 2020 - 2021

10.2.2.5.5.2. Market Forecast, 2022 - 2030

10.3. Key Segment for Channeling Investments

10.3.1. By Patient Type

11. Global Non-Alcoholic Steatohepatitis Diagnostics Market Analysis and Forecasts, 2022 – 2030

11.1. Overview

11.2. Global Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By End-User

11.2.1. Hospitals and Clinics

11.2.1.1.  Definition

11.2.1.2.  Market Estimation and Penetration, 2020 - 2021

11.2.1.3.  Market Forecast, 2022 - 2030

11.2.1.4.  Compound Annual Growth Rate (CAGR)

11.2.1.5.  Regional Bifurcation

11.2.1.5.1.  North America

11.2.1.5.1.1. Market Estimation, 2020 - 2021

11.2.1.5.1.2. Market Forecast, 2022 - 2030

11.2.1.5.2.  Europe

11.2.1.5.2.1. Market Estimation, 2020 - 2021

11.2.1.5.2.2. Market Forecast, 2022 - 2030

11.2.1.5.3.  Asia Pacific

11.2.1.5.3.1. Market Estimation, 2020 - 2021

11.2.1.5.3.2. Market Forecast, 2022 - 2030

11.2.1.5.4.  Middle East and Africa

11.2.1.5.4.1. Market Estimation, 2020 - 2021

11.2.1.5.4.2. Market Forecast, 2022 - 2030

11.2.1.5.5.  Latin America

11.2.1.5.5.1. Market Estimation, 2020 - 2021

11.2.1.5.5.2. Market Forecast, 2022 - 2030

11.2.2. Research and Academic Institutes

11.2.2.1.  Definition

11.2.2.2.  Market Estimation and Penetration, 2020 - 2021

11.2.2.3.  Market Forecast, 2022 - 2030

11.2.2.4.  Compound Annual Growth Rate (CAGR)

11.2.2.5.  Regional Bifurcation

11.2.2.5.1.  North America

11.2.2.5.1.1. Market Estimation, 2020 - 2021

11.2.2.5.1.2. Market Forecast, 2022 - 2030

11.2.2.5.2.  Europe

11.2.2.5.2.1. Market Estimation, 2020 - 2021

11.2.2.5.2.2. Market Forecast, 2022 - 2030

11.2.2.5.3.  Asia Pacific

11.2.2.5.3.1. Market Estimation, 2020 - 2021

11.2.2.5.3.2. Market Forecast, 2022 - 2030

11.2.2.5.4.  Middle East and Africa

11.2.2.5.4.1. Market Estimation, 2020 - 2021

11.2.2.5.4.2. Market Forecast, 2022 - 2030

11.2.2.5.5.  Latin America

11.2.2.5.5.1. Market Estimation, 2020 - 2021

11.2.2.5.5.2. Market Forecast, 2022 - 2030

11.2.3. Diagnostics

11.2.3.1.  Definition

11.2.3.2.  Market Estimation and Penetration, 2020 - 2021

11.2.3.3.  Market Forecast, 2022 - 2030

11.2.3.4.  Compound Annual Growth Rate (CAGR)

11.2.3.5.  Regional Bifurcation

11.2.3.5.1.  North America

11.2.3.5.1.1. Market Estimation, 2020 - 2021

11.2.3.5.1.2. Market Forecast, 2022 - 2030

11.2.3.5.2.  Europe

11.2.3.5.2.1. Market Estimation, 2020 - 2021

11.2.3.5.2.2. Market Forecast, 2022 - 2030

11.2.3.5.3.  Asia Pacific

11.2.3.5.3.1. Market Estimation, 2020 - 2021

11.2.3.5.3.2. Market Forecast, 2022 - 2030

11.2.3.5.4.  Middle East and Africa

11.2.3.5.4.1. Market Estimation, 2020 - 2021

11.2.3.5.4.2. Market Forecast, 2022 - 2030

11.2.3.5.5.  Latin America

11.2.3.5.5.1. Market Estimation, 2020 - 2021

11.2.3.5.5.2. Market Forecast, 2022 - 2030

11.2.4. Pharma Companies

11.2.4.1.  Definition

11.2.4.2.  Market Estimation and Penetration, 2020 - 2021

11.2.4.3.  Market Forecast, 2022 - 2030

11.2.4.4.  Compound Annual Growth Rate (CAGR)

11.2.4.5.  Regional Bifurcation

11.2.4.5.1.  North America

11.2.4.5.1.1. Market Estimation, 2020 - 2021

11.2.4.5.1.2. Market Forecast, 2022 - 2030

11.2.4.5.2.  Europe

11.2.4.5.2.1. Market Estimation, 2020 - 2021

11.2.4.5.2.2. Market Forecast, 2022 - 2030

11.2.4.5.3.  Asia Pacific

11.2.4.5.3.1. Market Estimation, 2020 - 2021

11.2.4.5.3.2. Market Forecast, 2022 - 2030

11.2.4.5.4.  Middle East and Africa

11.2.4.5.4.1. Market Estimation, 2020 - 2021

11.2.4.5.4.2. Market Forecast, 2022 - 2030

11.2.4.5.5.  Latin America

11.2.4.5.5.1. Market Estimation, 2020 - 2021

11.2.4.5.5.2. Market Forecast, 2022 - 2030

11.2.5. Others

11.2.5.1.  Definition

11.2.5.2.  Market Estimation and Penetration, 2020 - 2021

11.2.5.3.  Market Forecast, 2022 - 2030

11.2.5.4.  Compound Annual Growth Rate (CAGR)

11.2.5.5.  Regional Bifurcation

11.2.5.5.1.  North America

11.2.5.5.1.1. Market Estimation, 2020 - 2021

11.2.5.5.1.2. Market Forecast, 2022 - 2030

11.2.5.5.2.  Europe

11.2.5.5.2.1. Market Estimation, 2020 - 2021

11.2.5.5.2.2. Market Forecast, 2022 - 2030

11.2.5.5.3.  Asia Pacific

11.2.5.5.3.1. Market Estimation, 2020 - 2021

11.2.5.5.3.2. Market Forecast, 2022 - 2030

11.2.5.5.4.  Middle East and Africa

11.2.5.5.4.1. Market Estimation, 2020 - 2021

11.2.5.5.4.2. Market Forecast, 2022 - 2030

11.2.5.5.5.  Latin America

11.2.5.5.5.1. Market Estimation, 2020 - 2021

11.2.5.5.5.2. Market Forecast, 2022 - 2030

11.3. Key Segment for Channeling Investments

11.3.1. By End-User

12. North America Non-Alcoholic Steatohepatitis Diagnostics Market Analysis and Forecasts, 2022 - 2030

12.1. Overview

12.1.1. North America Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn)

12.2. North America Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings

12.2.1. Diagnostic Assays

12.2.2.  Others

12.3. North America Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Diagnosis

12.3.1. Serum Biomarkers

12.3.2. Liver Biopsy and liver enzyme testing

12.3.3. Echography

12.3.4. Histological assessment of liver tissue

12.3.5. Physical Examination

12.3.6. Blood Tests

12.3.7. Imaging Tests

12.3.8. Magnetic resonance imaging (MRI)

12.3.8.1.  Ultrasound

12.3.8.2.  Others

12.3.9. Others

12.4. North America Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Patient Type

12.4.1. Adult

12.4.2. Pediatric

12.5. North America Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By End-User

12.5.1. Hospitals and Clinics

12.5.2. Research and Academic Institutes

12.5.3. Diagnostics

12.5.4. Pharma Companies

12.5.5. Others

12.6. North America Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Country

12.6.1. U.S

12.6.1.1.  U.S Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings

12.6.1.1.1.  Diagnostic Assays

12.6.1.1.2.   Others

12.6.1.2.  U.S Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Diagnosis

12.6.1.2.1.  Serum Biomarkers

12.6.1.2.2.  Liver Biopsy and liver enzyme testing

12.6.1.2.3.  Echography

12.6.1.2.4.  Histological assessment of liver tissue

12.6.1.2.5.  Physical Examination

12.6.1.2.6.  Blood Tests

12.6.1.2.7.  Imaging Tests

12.6.1.2.8.  Magnetic resonance imaging (MRI)

12.6.1.2.8.1. Ultrasound

12.6.1.2.8.2. Others

12.6.1.2.9.  Others

12.6.1.3.  U.S Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Patient Type

12.6.1.3.1.  Adult

12.6.1.3.2.  Pediatric

12.6.1.4.  U.S Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By End-User

12.6.1.4.1.  Hospitals and Clinics

12.6.1.4.2.  Research and Academic Institutes

12.6.1.4.3.  Diagnostics

12.6.1.4.4.  Pharma Companies

12.6.1.4.5.  Others

12.6.2. Canada

12.6.2.1.  Canada Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings

12.6.2.1.1.  Diagnostic Assays

12.6.2.1.2.   Others

12.6.2.2.  Canada Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Diagnosis

12.6.2.2.1.  Serum Biomarkers

12.6.2.2.2.  Liver Biopsy and liver enzyme testing

12.6.2.2.3.  Echography

12.6.2.2.4.  Histological assessment of liver tissue

12.6.2.2.5.  Physical Examination

12.6.2.2.6.  Blood Tests

12.6.2.2.7.  Imaging Tests

12.6.2.2.8.  Magnetic resonance imaging (MRI)

12.6.2.2.8.1. Ultrasound

12.6.2.2.8.2. Others

12.6.2.2.9.  Others

12.6.2.3.  Canada Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Patient Type

12.6.2.3.1.  Adult

12.6.2.3.2.  Pediatric

12.6.2.4.  Canada Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By End-User

12.6.2.4.1.  Hospitals and Clinics

12.6.2.4.2.  Research and Academic Institutes

12.6.2.4.3.  Diagnostics

12.6.2.4.4.  Pharma Companies

12.6.2.4.5.  Others

12.6.3. Mexico

12.6.3.1.  Mexico Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings

12.6.3.1.1.  Diagnostic Assays

12.6.3.1.2.   Others

12.6.3.2.  Mexico Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Diagnosis

12.6.3.2.1.  Serum Biomarkers

12.6.3.2.2.  Liver Biopsy and liver enzyme testing

12.6.3.2.3.  Echography

12.6.3.2.4.  Histological assessment of liver tissue

12.6.3.2.5.  Physical Examination

12.6.3.2.6.  Blood Tests

12.6.3.2.7.  Imaging Tests

12.6.3.2.8.  Magnetic resonance imaging (MRI)

12.6.3.2.8.1. Ultrasound

12.6.3.2.8.2. Others

12.6.3.2.9.  Others

12.6.3.3.  Mexico Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Patient Type

12.6.3.3.1.  Adult

12.6.3.3.2.  Pediatric

12.6.3.4.  Mexico Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By End-User

12.6.3.4.1.  Hospitals and Clinics

12.6.3.4.2.  Research and Academic Institutes

12.6.3.4.3.  Diagnostics

12.6.3.4.4.  Pharma Companies

12.6.3.4.5.  Others

12.6.4. Rest of North America

12.6.4.1.  Rest of North America Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings

12.6.4.1.1.  Diagnostic Assays

12.6.4.1.2.   Others

12.6.4.2.  Rest of North America Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Diagnosis

12.6.4.2.1.  Serum Biomarkers

12.6.4.2.2.  Liver Biopsy and liver enzyme testing

12.6.4.2.3.  Echography

12.6.4.2.4.  Histological assessment of liver tissue

12.6.4.2.5.  Physical Examination

12.6.4.2.6.  Blood Tests

12.6.4.2.7.  Imaging Tests

12.6.4.2.8.  Magnetic resonance imaging (MRI)

12.6.4.2.8.1. Ultrasound

12.6.4.2.8.2. Others

12.6.4.2.9.  Others

12.6.4.3.  Rest of North America Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Patient Type

12.6.4.3.1.  Adult

12.6.4.3.2.  Pediatric

12.6.4.4.  Rest of North America Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By End-User

12.6.4.4.1.  Hospitals and Clinics

12.6.4.4.2.  Research and Academic Institutes

12.6.4.4.3.  Diagnostics

12.6.4.4.4.  Pharma Companies

12.6.4.4.5.  Others

12.7. Key Segment for Channeling Investments

12.7.1. By Country

12.7.2. By Offerings

12.7.3. By Diagnosis

12.7.4. By Patient Type

12.7.5. By End-User

13. Europe Non-Alcoholic Steatohepatitis Diagnostics Market Analysis and Forecasts, 2022 - 2030

13.1. Overview

13.1.1. Europe Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn)

13.2. Europe Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings

13.2.1. Diagnostic Assays

13.2.2.  Others

13.3. Europe Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Diagnosis

13.3.1. Serum Biomarkers

13.3.2. Liver Biopsy and liver enzyme testing

13.3.3. Echography

13.3.4. Histological assessment of liver tissue

13.3.5. Physical Examination

13.3.6. Blood Tests

13.3.7. Imaging Tests

13.3.8. Magnetic resonance imaging (MRI)

13.3.8.1.  Ultrasound

13.3.8.2.  Others

13.3.9. Others

13.4. Europe Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Patient Type

13.4.1. Adult

13.4.2. Pediatric

13.5. Europe Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By End-User

13.5.1. Hospitals and Clinics

13.5.2. Research and Academic Institutes

13.5.3. Diagnostics

13.5.4. Pharma Companies

13.5.5. Others

13.6. Europe Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Country

13.6.1. France

13.6.1.1.  France Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings

13.6.1.1.1.  Diagnostic Assays

13.6.1.1.2.   Others

13.6.1.2.  France Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Diagnosis

13.6.1.2.1.  Serum Biomarkers

13.6.1.2.2.  Liver Biopsy and liver enzyme testing

13.6.1.2.3.  Echography

13.6.1.2.4.  Histological assessment of liver tissue

13.6.1.2.5.  Physical Examination

13.6.1.2.6.  Blood Tests

13.6.1.2.7.  Imaging Tests

13.6.1.2.8.  Magnetic resonance imaging (MRI)

13.6.1.2.8.1. Ultrasound

13.6.1.2.8.2. Others

13.6.1.2.9.  Others

13.6.1.3.  France Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Patient Type

13.6.1.3.1.  Adult

13.6.1.3.2.  Pediatric

13.6.1.4.  France Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By End-User

13.6.1.4.1.  Hospitals and Clinics

13.6.1.4.2.  Research and Academic Institutes

13.6.1.4.3.  Diagnostics

13.6.1.4.4.  Pharma Companies

13.6.1.4.5.  Others

13.6.2. The UK

13.6.2.1.  The UK Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings

13.6.2.1.1.  Diagnostic Assays

13.6.2.1.2.   Others

13.6.2.2.  The UK Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Diagnosis

13.6.2.2.1.  Serum Biomarkers

13.6.2.2.2.  Liver Biopsy and liver enzyme testing

13.6.2.2.3.  Echography

13.6.2.2.4.  Histological assessment of liver tissue

13.6.2.2.5.  Physical Examination

13.6.2.2.6.  Blood Tests

13.6.2.2.7.  Imaging Tests

13.6.2.2.8.  Magnetic resonance imaging (MRI)

13.6.2.2.8.1. Ultrasound

13.6.2.2.8.2. Others

13.6.2.2.9.  Others

13.6.2.3.  The UK Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Patient Type

13.6.2.3.1.  Adult

13.6.2.3.2.  Pediatric

13.6.2.4.  The UK Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By End-User

13.6.2.4.1.  Hospitals and Clinics

13.6.2.4.2.  Research and Academic Institutes

13.6.2.4.3.  Diagnostics

13.6.2.4.4.  Pharma Companies

13.6.2.4.5.  Others

13.6.3. Spain

13.6.3.1.  Spain Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings

13.6.3.1.1.  Diagnostic Assays

13.6.3.1.2.   Others

13.6.3.2.  Spain Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Diagnosis

13.6.3.2.1.  Serum Biomarkers

13.6.3.2.2.  Liver Biopsy and liver enzyme testing

13.6.3.2.3.  Echography

13.6.3.2.4.  Histological assessment of liver tissue

13.6.3.2.5.  Physical Examination

13.6.3.2.6.  Blood Tests

13.6.3.2.7.  Imaging Tests

13.6.3.2.8.  Magnetic resonance imaging (MRI)

13.6.3.2.8.1. Ultrasound

13.6.3.2.8.2. Others

13.6.3.2.9.  Others

13.6.3.3.  Spain Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Patient Type

13.6.3.3.1.  Adult

13.6.3.3.2.  Pediatric

13.6.3.4.  Spain Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By End-User

13.6.3.4.1.  Hospitals and Clinics

13.6.3.4.2.  Research and Academic Institutes

13.6.3.4.3.  Diagnostics

13.6.3.4.4.  Pharma Companies

13.6.3.4.5.  Others

13.6.4. Germany

13.6.4.1.  Germany Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings

13.6.4.1.1.  Diagnostic Assays

13.6.4.1.2.   Others

13.6.4.2.  Germany Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Diagnosis

13.6.4.2.1.  Serum Biomarkers

13.6.4.2.2.  Liver Biopsy and liver enzyme testing

13.6.4.2.3.  Echography

13.6.4.2.4.  Histological assessment of liver tissue

13.6.4.2.5.  Physical Examination

13.6.4.2.6.  Blood Tests

13.6.4.2.7.  Imaging Tests

13.6.4.2.8.  Magnetic resonance imaging (MRI)

13.6.4.2.8.1. Ultrasound

13.6.4.2.8.2. Others

13.6.4.2.9.  Others

13.6.4.3.  Germany Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Patient Type

13.6.4.3.1.  Adult

13.6.4.3.2.  Pediatric

13.6.4.4.  Germany Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By End-User

13.6.4.4.1.  Hospitals and Clinics

13.6.4.4.2.  Research and Academic Institutes

13.6.4.4.3.  Diagnostics

13.6.4.4.4.  Pharma Companies

13.6.4.4.5.  Others

13.6.5. Italy

13.6.5.1.  Italy Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings

13.6.5.1.1.  Diagnostic Assays

13.6.5.1.2.   Others

13.6.5.2.  Italy Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Diagnosis

13.6.5.2.1.  Serum Biomarkers

13.6.5.2.2.  Liver Biopsy and liver enzyme testing

13.6.5.2.3.  Echography

13.6.5.2.4.  Histological assessment of liver tissue

13.6.5.2.5.  Physical Examination

13.6.5.2.6.  Blood Tests

13.6.5.2.7.  Imaging Tests

13.6.5.2.8.  Magnetic resonance imaging (MRI)

13.6.5.2.8.1. Ultrasound

13.6.5.2.8.2. Others

13.6.5.2.9.  Others

13.6.5.3.  Italy Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Patient Type

13.6.5.3.1.  Adult

13.6.5.3.2.  Pediatric

13.6.5.4.  Italy Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By End-User

13.6.5.4.1.  Hospitals and Clinics

13.6.5.4.2.  Research and Academic Institutes

13.6.5.4.3.  Diagnostics

13.6.5.4.4.  Pharma Companies

13.6.5.4.5.  Others

13.6.6. Nordic Countries

13.6.6.1.  Nordic Countries Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings

13.6.6.1.1.  Diagnostic Assays

13.6.6.1.2.   Others

13.6.6.2.  Nordic Countries Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Diagnosis

13.6.6.2.1.  Serum Biomarkers

13.6.6.2.2.  Liver Biopsy and liver enzyme testing

13.6.6.2.3.  Echography

13.6.6.2.4.  Histological assessment of liver tissue

13.6.6.2.5.  Physical Examination

13.6.6.2.6.  Blood Tests

13.6.6.2.7.  Imaging Tests

13.6.6.2.8.  Magnetic resonance imaging (MRI)

13.6.6.2.8.1. Ultrasound

13.6.6.2.8.2. Others

13.6.6.2.9.  Others

13.6.6.3.  Nordic Countries Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Patient Type

13.6.6.3.1.  Adult

13.6.6.3.2.  Pediatric

13.6.6.4.  Nordic Countries Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By End-User

13.6.6.4.1.  Hospitals and Clinics

13.6.6.4.2.  Research and Academic Institutes

13.6.6.4.3.  Diagnostics

13.6.6.4.4.  Pharma Companies

13.6.6.4.5.  Others

13.6.6.5.  Nordic Countries Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Country

13.6.6.5.1.  Denmark

13.6.6.5.2.  Finland

13.6.6.5.3.  Iceland

13.6.6.5.4.  Sweden

13.6.6.5.5.  Norway

13.6.7. Benelux Union

13.6.7.1.  Benelux Union Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings

13.6.7.1.1.  Diagnostic Assays

13.6.7.1.2.   Others

13.6.7.2.  Benelux Union Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Diagnosis

13.6.7.2.1.  Serum Biomarkers

13.6.7.2.2.  Liver Biopsy and liver enzyme testing

13.6.7.2.3.  Echography

13.6.7.2.4.  Histological assessment of liver tissue

13.6.7.2.5.  Physical Examination

13.6.7.2.6.  Blood Tests

13.6.7.2.7.  Imaging Tests

13.6.7.2.8.  Magnetic resonance imaging (MRI)

13.6.7.2.8.1. Ultrasound

13.6.7.2.8.2. Others

13.6.7.2.9.  Others

13.6.7.3.  Benelux Union Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Patient Type

13.6.7.3.1.  Adult

13.6.7.3.2.  Pediatric

13.6.7.4.  Benelux Union Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By End-User

13.6.7.4.1.  Hospitals and Clinics

13.6.7.4.2.  Research and Academic Institutes

13.6.7.4.3.  Diagnostics

13.6.7.4.4.  Pharma Companies

13.6.7.4.5.  Others

13.6.7.5.  Benelux Union Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Country

13.6.7.5.1.  Belgium

13.6.7.5.2.  The Netherlands

13.6.7.5.3.  Luxembourg

13.6.8. Rest of Europe

13.6.8.1.  Rest of Europe Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings

13.6.8.1.1.  Diagnostic Assays

13.6.8.1.2.   Others

13.6.8.2.  Rest of Europe Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Diagnosis

13.6.8.2.1.  Serum Biomarkers

13.6.8.2.2.  Liver Biopsy and liver enzyme testing

13.6.8.2.3.  Echography

13.6.8.2.4.  Histological assessment of liver tissue

13.6.8.2.5.  Physical Examination

13.6.8.2.6.  Blood Tests

13.6.8.2.7.  Imaging Tests

13.6.8.2.8.  Magnetic resonance imaging (MRI)

13.6.8.2.8.1. Ultrasound

13.6.8.2.8.2. Others

13.6.8.2.9.  Others

13.6.8.3.  Rest of Europe Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Patient Type

13.6.8.3.1.  Adult

13.6.8.3.2.  Pediatric

13.6.8.4.  Rest of Europe Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By End-User

13.6.8.4.1.  Hospitals and Clinics

13.6.8.4.2.  Research and Academic Institutes

13.6.8.4.3.  Diagnostics

13.6.8.4.4.  Pharma Companies

13.6.8.4.5.  Others

13.7. Key Segment for Channeling Investments

13.7.1. By Country

13.7.2. By Offerings

13.7.3. By Diagnosis

13.7.4. By Patient Type

13.7.5. By End-User

14. Asia Pacific Non-Alcoholic Steatohepatitis Diagnostics Market Analysis and Forecasts, 2022 - 2030

14.1. Overview

14.1.1. Asia Pacific Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn)

14.2. Asia Pacific Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings

14.2.1. Diagnostic Assays

14.2.2.  Others

14.3. Asia Pacific Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Diagnosis

14.3.1. Serum Biomarkers

14.3.2. Liver Biopsy and liver enzyme testing

14.3.3. Echography

14.3.4. Histological assessment of liver tissue

14.3.5. Physical Examination

14.3.6. Blood Tests

14.3.7. Imaging Tests

14.3.8. Magnetic resonance imaging (MRI)

14.3.8.1.  Ultrasound

14.3.8.2.  Others

14.3.9. Others

14.4. Asia Pacific Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Patient Type

14.4.1. Adult

14.4.2. Pediatric

14.5. Asia Pacific Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By End-User

14.5.1. Hospitals and Clinics

14.5.2. Research and Academic Institutes

14.5.3. Diagnostics

14.5.4. Pharma Companies

14.5.5. Others

14.6. Asia Pacific Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Country

14.6.1. China

14.6.1.1.  China Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings

14.6.1.1.1.  Diagnostic Assays

14.6.1.1.2.   Others

14.6.1.2.  China Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Diagnosis

14.6.1.2.1.  Serum Biomarkers

14.6.1.2.2.  Liver Biopsy and liver enzyme testing

14.6.1.2.3.  Echography

14.6.1.2.4.  Histological assessment of liver tissue

14.6.1.2.5.  Physical Examination

14.6.1.2.6.  Blood Tests

14.6.1.2.7.  Imaging Tests

14.6.1.2.8.  Magnetic resonance imaging (MRI)

14.6.1.2.8.1. Ultrasound

14.6.1.2.8.2. Others

14.6.1.2.9.  Others

14.6.1.3.  China Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Patient Type

14.6.1.3.1.  Adult

14.6.1.3.2.  Pediatric

14.6.1.4.  China Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By End-User

14.6.1.4.1.  Hospitals and Clinics

14.6.1.4.2.  Research and Academic Institutes

14.6.1.4.3.  Diagnostics

14.6.1.4.4.  Pharma Companies

14.6.1.4.5.  Others

14.6.2. Japan

14.6.2.1.  Japan Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings

14.6.2.1.1.  Diagnostic Assays

14.6.2.1.2.   Others

14.6.2.2.  Japan Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Diagnosis

14.6.2.2.1.  Serum Biomarkers

14.6.2.2.2.  Liver Biopsy and liver enzyme testing

14.6.2.2.3.  Echography

14.6.2.2.4.  Histological assessment of liver tissue

14.6.2.2.5.  Physical Examination

14.6.2.2.6.  Blood Tests

14.6.2.2.7.  Imaging Tests

14.6.2.2.8.  Magnetic resonance imaging (MRI)

14.6.2.2.8.1. Ultrasound

14.6.2.2.8.2. Others

14.6.2.2.9.  Others

14.6.2.3.  Japan Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Patient Type

14.6.2.3.1.  Adult

14.6.2.3.2.  Pediatric

14.6.2.4.  Japan Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By End-User

14.6.2.4.1.  Hospitals and Clinics

14.6.2.4.2.  Research and Academic Institutes

14.6.2.4.3.  Diagnostics

14.6.2.4.4.  Pharma Companies

14.6.2.4.5.  Others

14.6.3. India

14.6.3.1.  India Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings

14.6.3.1.1.  Diagnostic Assays

14.6.3.1.2.   Others

14.6.3.2.  India Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Diagnosis

14.6.3.2.1.  Serum Biomarkers

14.6.3.2.2.  Liver Biopsy and liver enzyme testing

14.6.3.2.3.  Echography

14.6.3.2.4.  Histological assessment of liver tissue

14.6.3.2.5.  Physical Examination

14.6.3.2.6.  Blood Tests

14.6.3.2.7.  Imaging Tests

14.6.3.2.8.  Magnetic resonance imaging (MRI)

14.6.3.2.8.1. Ultrasound

14.6.3.2.8.2. Others

14.6.3.2.9.  Others

14.6.3.3.  India Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Patient Type

14.6.3.3.1.  Adult

14.6.3.3.2.  Pediatric

14.6.3.4.  India Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By End-User

14.6.3.4.1.  Hospitals and Clinics

14.6.3.4.2.  Research and Academic Institutes

14.6.3.4.3.  Diagnostics

14.6.3.4.4.  Pharma Companies

14.6.3.4.5.  Others

14.6.4. New Zealand

14.6.4.1.  New Zealand Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings

14.6.4.1.1.  Diagnostic Assays

14.6.4.1.2.   Others

14.6.4.2.  New Zealand Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Diagnosis

14.6.4.2.1.  Serum Biomarkers

14.6.4.2.2.  Liver Biopsy and liver enzyme testing

14.6.4.2.3.  Echography

14.6.4.2.4.  Histological assessment of liver tissue

14.6.4.2.5.  Physical Examination

14.6.4.2.6.  Blood Tests

14.6.4.2.7.  Imaging Tests

14.6.4.2.8.  Magnetic resonance imaging (MRI)

14.6.4.2.8.1. Ultrasound

14.6.4.2.8.2. Others

14.6.4.2.9.  Others

14.6.4.3.  New Zealand Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Patient Type

14.6.4.3.1.  Adult

14.6.4.3.2.  Pediatric

14.6.4.4.  New Zealand Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By End-User

14.6.4.4.1.  Hospitals and Clinics

14.6.4.4.2.  Research and Academic Institutes

14.6.4.4.3.  Diagnostics

14.6.4.4.4.  Pharma Companies

14.6.4.4.5.  Others

14.6.5. Australia

14.6.5.1.  Australia Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings

14.6.5.1.1.  Diagnostic Assays

14.6.5.1.2.   Others

14.6.5.2.  Australia Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Diagnosis

14.6.5.2.1.  Serum Biomarkers

14.6.5.2.2.  Liver Biopsy and liver enzyme testing

14.6.5.2.3.  Echography

14.6.5.2.4.  Histological assessment of liver tissue

14.6.5.2.5.  Physical Examination

14.6.5.2.6.  Blood Tests

14.6.5.2.7.  Imaging Tests

14.6.5.2.8.  Magnetic resonance imaging (MRI)

14.6.5.2.8.1. Ultrasound

14.6.5.2.8.2. Others

14.6.5.2.9.  Others

14.6.5.3.  Australia Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Patient Type

14.6.5.3.1.  Adult

14.6.5.3.2.  Pediatric

14.6.5.4.  Australia Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By End-User

14.6.5.4.1.  Hospitals and Clinics

14.6.5.4.2.  Research and Academic Institutes

14.6.5.4.3.  Diagnostics

14.6.5.4.4.  Pharma Companies

14.6.5.4.5.  Others

14.6.6. South Korea

14.6.6.1.  South Korea Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings

14.6.6.1.1.  Diagnostic Assays

14.6.6.1.2.   Others

14.6.6.2.  South Korea Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Diagnosis

14.6.6.2.1.  Serum Biomarkers

14.6.6.2.2.  Liver Biopsy and liver enzyme testing

14.6.6.2.3.  Echography

14.6.6.2.4.  Histological assessment of liver tissue

14.6.6.2.5.  Physical Examination

14.6.6.2.6.  Blood Tests

14.6.6.2.7.  Imaging Tests

14.6.6.2.8.  Magnetic resonance imaging (MRI)

14.6.6.2.8.1. Ultrasound

14.6.6.2.8.2. Others

14.6.6.2.9.  Others

14.6.6.3.  South Korea Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Patient Type

14.6.6.3.1.  Adult

14.6.6.3.2.  Pediatric

14.6.6.4.  South Korea Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By End-User

14.6.6.4.1.  Hospitals and Clinics

14.6.6.4.2.  Research and Academic Institutes

14.6.6.4.3.  Diagnostics

14.6.6.4.4.  Pharma Companies

14.6.6.4.5.  Others

14.6.7. Southeast Asia

14.6.7.1.  Southeast Asia Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings

14.6.7.1.1.  Diagnostic Assays

14.6.7.1.2.   Others

14.6.7.2.  Southeast Asia Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Diagnosis

14.6.7.2.1.  Serum Biomarkers

14.6.7.2.2.  Liver Biopsy and liver enzyme testing

14.6.7.2.3.  Echography

14.6.7.2.4.  Histological assessment of liver tissue

14.6.7.2.5.  Physical Examination

14.6.7.2.6.  Blood Tests

14.6.7.2.7.  Imaging Tests

14.6.7.2.8.  Magnetic resonance imaging (MRI)

14.6.7.2.8.1. Ultrasound

14.6.7.2.8.2. Others

14.6.7.2.9.  Others

14.6.7.3.  Southeast Asia Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Patient Type

14.6.7.3.1.  Adult

14.6.7.3.2.  Pediatric

14.6.7.4.  Southeast Asia Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By End-User

14.6.7.4.1.  Hospitals and Clinics

14.6.7.4.2.  Research and Academic Institutes

14.6.7.4.3.  Diagnostics

14.6.7.4.4.  Pharma Companies

14.6.7.4.5.  Others

14.6.7.5.  Southeast Asia Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Country

14.6.7.5.1.  Indonesia

14.6.7.5.2.  Thailand

14.6.7.5.3.  Malaysia

14.6.7.5.4.  Singapore

14.6.7.5.5.  Rest of Southeast Asia

14.6.8. Rest of Asia Pacific

14.6.8.1.  Rest of Asia Pacific Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings

14.6.8.1.1.  Diagnostic Assays

14.6.8.1.2.   Others

14.6.8.2.  Rest of Asia Pacific Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Diagnosis

14.6.8.2.1.  Serum Biomarkers

14.6.8.2.2.  Liver Biopsy and liver enzyme testing

14.6.8.2.3.  Echography

14.6.8.2.4.  Histological assessment of liver tissue

14.6.8.2.5.  Physical Examination

14.6.8.2.6.  Blood Tests

14.6.8.2.7.  Imaging Tests

14.6.8.2.8.  Magnetic resonance imaging (MRI)

14.6.8.2.8.1. Ultrasound

14.6.8.2.8.2. Others

14.6.8.2.9.  Others

14.6.8.3.  Rest of Asia Pacific Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Patient Type

14.6.8.3.1.  Adult

14.6.8.3.2.  Pediatric

14.6.8.4.  Rest of Asia Pacific Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By End-User

14.6.8.4.1.  Hospitals and Clinics

14.6.8.4.2.  Research and Academic Institutes

14.6.8.4.3.  Diagnostics

14.6.8.4.4.  Pharma Companies

14.6.8.4.5.  Others

14.7. Key Segment for Channeling Investments

14.7.1. By Country

14.7.2. By Offerings

14.7.3. By Diagnosis

14.7.4. By Patient Type

14.7.5. By End-User

15. Middle East and Africa Non-Alcoholic Steatohepatitis Diagnostics Market Analysis and Forecasts, 2022 - 2030

15.1. Overview

15.1.1. Middle East and Africa Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn)

15.2. Middle East and Africa Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings

15.2.1. Diagnostic Assays

15.2.2.  Others

15.3. Middle East and Africa Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Diagnosis

15.3.1. Serum Biomarkers

15.3.2. Liver Biopsy and liver enzyme testing

15.3.3. Echography

15.3.4. Histological assessment of liver tissue

15.3.5. Physical Examination

15.3.6. Blood Tests

15.3.7. Imaging Tests

15.3.8. Magnetic resonance imaging (MRI)

15.3.8.1.  Ultrasound

15.3.8.2.  Others

15.3.9. Others

15.4. Middle East and Africa Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Patient Type

15.4.1. Adult

15.4.2. Pediatric

15.5. Middle East and Africa Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By End-User

15.5.1. Hospitals and Clinics

15.5.2. Research and Academic Institutes

15.5.3. Diagnostics

15.5.4. Pharma Companies

15.5.5. Others

15.6. Middle East and Africa Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Country

15.6.1. Saudi Arabia

15.6.1.1.  Saudi Arabia Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings

15.6.1.1.1.  Diagnostic Assays

15.6.1.1.2.   Others

15.6.1.2.  Saudi Arabia Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Diagnosis

15.6.1.2.1.  Serum Biomarkers

15.6.1.2.2.  Liver Biopsy and liver enzyme testing

15.6.1.2.3.  Echography

15.6.1.2.4.  Histological assessment of liver tissue

15.6.1.2.5.  Physical Examination

15.6.1.2.6.  Blood Tests

15.6.1.2.7.  Imaging Tests

15.6.1.2.8.  Magnetic resonance imaging (MRI)

15.6.1.2.8.1. Ultrasound

15.6.1.2.8.2. Others

15.6.1.2.9.  Others

15.6.1.3.  Saudi Arabia Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Patient Type

15.6.1.3.1.  Adult

15.6.1.3.2.  Pediatric

15.6.1.4.  Saudi Arabia Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By End-User

15.6.1.4.1.  Hospitals and Clinics

15.6.1.4.2.  Research and Academic Institutes

15.6.1.4.3.  Diagnostics

15.6.1.4.4.  Pharma Companies

15.6.1.4.5.  Others

15.6.2. UAE

15.6.2.1.  UAE Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings

15.6.2.1.1.  Diagnostic Assays

15.6.2.1.2.   Others

15.6.2.2.  UAE Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Diagnosis

15.6.2.2.1.  Serum Biomarkers

15.6.2.2.2.  Liver Biopsy and liver enzyme testing

15.6.2.2.3.  Echography

15.6.2.2.4.  Histological assessment of liver tissue

15.6.2.2.5.  Physical Examination

15.6.2.2.6.  Blood Tests

15.6.2.2.7.  Imaging Tests

15.6.2.2.8.  Magnetic resonance imaging (MRI)

15.6.2.2.8.1. Ultrasound

15.6.2.2.8.2. Others

15.6.2.2.9.  Others

15.6.2.3.  UAE Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Patient Type

15.6.2.3.1.  Adult

15.6.2.3.2.  Pediatric

15.6.2.4.  UAE Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By End-User

15.6.2.4.1.  Hospitals and Clinics

15.6.2.4.2.  Research and Academic Institutes

15.6.2.4.3.  Diagnostics

15.6.2.4.4.  Pharma Companies

15.6.2.4.5.  Others

15.6.3. Egypt

15.6.3.1.  Egypt Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings

15.6.3.1.1.  Diagnostic Assays

15.6.3.1.2.   Others

15.6.3.2.  Egypt Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Diagnosis

15.6.3.2.1.  Serum Biomarkers

15.6.3.2.2.  Liver Biopsy and liver enzyme testing

15.6.3.2.3.  Echography

15.6.3.2.4.  Histological assessment of liver tissue

15.6.3.2.5.  Physical Examination

15.6.3.2.6.  Blood Tests

15.6.3.2.7.  Imaging Tests

15.6.3.2.8.  Magnetic resonance imaging (MRI)

15.6.3.2.8.1. Ultrasound

15.6.3.2.8.2. Others

15.6.3.2.9.  Others

15.6.3.3.  Egypt Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Patient Type

15.6.3.3.1.  Adult

15.6.3.3.2.  Pediatric

15.6.3.4.  Egypt Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By End-User

15.6.3.4.1.  Hospitals and Clinics

15.6.3.4.2.  Research and Academic Institutes

15.6.3.4.3.  Diagnostics

15.6.3.4.4.  Pharma Companies

15.6.3.4.5.  Others

15.6.4. Kuwait

15.6.4.1.  Kuwait Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings

15.6.4.1.1.  Diagnostic Assays

15.6.4.1.2.   Others

15.6.4.2.  Kuwait Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Diagnosis

15.6.4.2.1.  Serum Biomarkers

15.6.4.2.2.  Liver Biopsy and liver enzyme testing

15.6.4.2.3.  Echography

15.6.4.2.4.  Histological assessment of liver tissue

15.6.4.2.5.  Physical Examination

15.6.4.2.6.  Blood Tests

15.6.4.2.7.  Imaging Tests

15.6.4.2.8.  Magnetic resonance imaging (MRI)

15.6.4.2.8.1. Ultrasound

15.6.4.2.8.2. Others

15.6.4.2.9.  Others

15.6.4.3.  Kuwait Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Patient Type

15.6.4.3.1.  Adult

15.6.4.3.2.  Pediatric

15.6.4.4.  Kuwait Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By End-User

15.6.4.4.1.  Hospitals and Clinics

15.6.4.4.2.  Research and Academic Institutes

15.6.4.4.3.  Diagnostics

15.6.4.4.4.  Pharma Companies

15.6.4.4.5.  Others

15.6.5. South Africa

15.6.5.1.  South Africa Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings

15.6.5.1.1.  Diagnostic Assays

15.6.5.1.2.   Others

15.6.5.2.  South Africa Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Diagnosis

15.6.5.2.1.  Serum Biomarkers

15.6.5.2.2.  Liver Biopsy and liver enzyme testing

15.6.5.2.3.  Echography

15.6.5.2.4.  Histological assessment of liver tissue

15.6.5.2.5.  Physical Examination

15.6.5.2.6.  Blood Tests

15.6.5.2.7.  Imaging Tests

15.6.5.2.8.  Magnetic resonance imaging (MRI)

15.6.5.2.8.1. Ultrasound

15.6.5.2.8.2. Others

15.6.5.2.9.  Others

15.6.5.3.  South Africa Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Patient Type

15.6.5.3.1.  Adult

15.6.5.3.2.  Pediatric

15.6.5.4.  South Africa Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By End-User

15.6.5.4.1.  Hospitals and Clinics

15.6.5.4.2.  Research and Academic Institutes

15.6.5.4.3.  Diagnostics

15.6.5.4.4.  Pharma Companies

15.6.5.4.5.  Others

15.6.6. Rest of Middle East & Africa

15.6.6.1.  Rest of Middle East & Africa Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings

15.6.6.1.1.  Diagnostic Assays

15.6.6.1.2.   Others

15.6.6.2.  Rest of Middle East & Africa Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Diagnosis

15.6.6.2.1.  Serum Biomarkers

15.6.6.2.2.  Liver Biopsy and liver enzyme testing

15.6.6.2.3.  Echography

15.6.6.2.4.  Histological assessment of liver tissue

15.6.6.2.5.  Physical Examination

15.6.6.2.6.  Blood Tests

15.6.6.2.7.  Imaging Tests

15.6.6.2.8.  Magnetic resonance imaging (MRI)

15.6.6.2.8.1. Ultrasound

15.6.6.2.8.2. Others

15.6.6.2.9.  Others

15.6.6.3.  Rest of Middle East & Africa Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Patient Type

15.6.6.3.1.  Adult

15.6.6.3.2.  Pediatric

15.6.6.4.  Rest of Middle East & Africa Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By End-User

15.6.6.4.1.  Hospitals and Clinics

15.6.6.4.2.  Research and Academic Institutes

15.6.6.4.3.  Diagnostics

15.6.6.4.4.  Pharma Companies

15.6.6.4.5.  Others

15.7. Key Segment for Channeling Investments

15.7.1. By Country

15.7.2. By Offerings

15.7.3. By Diagnosis

15.7.4. By Patient Type

15.7.5. By End-User

16. Latin America Non-Alcoholic Steatohepatitis Diagnostics Market Analysis and Forecasts, 2022 - 2030

16.1. Overview

16.1.1. Latin America Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn)

16.2. Latin America Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings

16.2.1. Diagnostic Assays

16.2.2.  Others

16.3. Latin America Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Diagnosis

16.3.1. Serum Biomarkers

16.3.2. Liver Biopsy and liver enzyme testing

16.3.3. Echography

16.3.4. Histological assessment of liver tissue

16.3.5. Physical Examination

16.3.6. Blood Tests

16.3.7. Imaging Tests

16.3.8. Magnetic resonance imaging (MRI)

16.3.8.1.  Ultrasound

16.3.8.2.  Others

16.3.9. Others

16.4. Latin America Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Patient Type

16.4.1. Adult

16.4.2. Pediatric

16.5. Latin America Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By End-User

16.5.1. Hospitals and Clinics

16.5.2. Research and Academic Institutes

16.5.3. Diagnostics

16.5.4. Pharma Companies

16.5.5. Others

16.6. Latin America Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Country

16.6.1. Brazil

16.6.1.1.  Brazil Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings

16.6.1.1.1.  Diagnostic Assays

16.6.1.1.2.   Others

16.6.1.2.  Brazil Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Diagnosis

16.6.1.2.1.  Serum Biomarkers

16.6.1.2.2.  Liver Biopsy and liver enzyme testing

16.6.1.2.3.  Echography

16.6.1.2.4.  Histological assessment of liver tissue

16.6.1.2.5.  Physical Examination

16.6.1.2.6.  Blood Tests

16.6.1.2.7.  Imaging Tests

16.6.1.2.8.  Magnetic resonance imaging (MRI)

16.6.1.2.8.1. Ultrasound

16.6.1.2.8.2. Others

16.6.1.2.9.  Others

16.6.1.3.  Brazil Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Patient Type

16.6.1.3.1.  Adult

16.6.1.3.2.  Pediatric

16.6.1.4.  Brazil Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By End-User

16.6.1.4.1.  Hospitals and Clinics

16.6.1.4.2.  Research and Academic Institutes

16.6.1.4.3.  Diagnostics

16.6.1.4.4.  Pharma Companies

16.6.1.4.5.  Others

16.6.2. Argentina

16.6.2.1.  Argentina Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings

16.6.2.1.1.  Diagnostic Assays

16.6.2.1.2.   Others

16.6.2.2.  Argentina Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Diagnosis

16.6.2.2.1.  Serum Biomarkers

16.6.2.2.2.  Liver Biopsy and liver enzyme testing

16.6.2.2.3.  Echography

16.6.2.2.4.  Histological assessment of liver tissue

16.6.2.2.5.  Physical Examination

16.6.2.2.6.  Blood Tests

16.6.2.2.7.  Imaging Tests

16.6.2.2.8.  Magnetic resonance imaging (MRI)

16.6.2.2.8.1. Ultrasound

16.6.2.2.8.2. Others

16.6.2.2.9.  Others

16.6.2.3.  Argentina Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Patient Type

16.6.2.3.1.  Adult

16.6.2.3.2.  Pediatric

16.6.2.4.  Argentina Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By End-User

16.6.2.4.1.  Hospitals and Clinics

16.6.2.4.2.  Research and Academic Institutes

16.6.2.4.3.  Diagnostics

16.6.2.4.4.  Pharma Companies

16.6.2.4.5.  Others

16.6.3. Rest of Latin America

16.6.3.1.  Rest of Latin America Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings

16.6.3.1.1.  Diagnostic Assays

16.6.3.1.2.   Others

16.6.3.2.  Rest of Latin America Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Diagnosis

16.6.3.2.1.  Serum Biomarkers

16.6.3.2.2.  Liver Biopsy and liver enzyme testing

16.6.3.2.3.  Echography

16.6.3.2.4.  Histological assessment of liver tissue

16.6.3.2.5.  Physical Examination

16.6.3.2.6.  Blood Tests

16.6.3.2.7.  Imaging Tests

16.6.3.2.8.  Magnetic resonance imaging (MRI)

16.6.3.2.8.1. Ultrasound

16.6.3.2.8.2. Others

16.6.3.2.9.  Others

16.6.3.3.  Rest of Latin America Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Patient Type

16.6.3.3.1.  Adult

16.6.3.3.2.  Pediatric

16.6.3.4.  Rest of Latin America Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By End-User

16.6.3.4.1.  Hospitals and Clinics

16.6.3.4.2.  Research and Academic Institutes

16.6.3.4.3.  Diagnostics

16.6.3.4.4.  Pharma Companies

16.6.3.4.5.  Others

16.7. Key Segment for Channeling Investments

16.7.1. By Country

16.7.2. By Offerings

16.7.3. By Diagnosis

16.7.4. By Patient Type

16.7.5. By End-User

17. Competitive Benchmarking

17.1. Brand Benchmarking

17.2. Market Share Analysis, 2021

17.3. Global Presence and Growth Strategies

17.3.1. Mergers and Acquisitions

17.3.2. Product Launches

17.3.3. Investments Trends

17.3.4. R&D Initiatives

18. Player Profiles

18.1. Galmed

18.1.1. Company Details

18.1.2. Company Overview

18.1.3. Product Offerings

18.1.4. Key Developments

18.1.5. Financial Analysis

18.1.6. SWOT Analysis

18.1.7. Business Strategies

18.2. Genfit

18.2.1. Company Details

18.2.2. Company Overview

18.2.3. Product Offerings

18.2.4. Key Developments

18.2.5. Financial Analysis

18.2.6. SWOT Analysis

18.2.7. Business Strategies

18.3. Intercept

18.3.1. Company Details

18.3.2. Company Overview

18.3.3. Product Offerings

18.3.4. Key Developments

18.3.5. Financial Analysis

18.3.6. SWOT Analysis

18.3.7. Business Strategies

18.4. Other Market Participants

19. Key Findings

 

Note: This ToC is tentative and can be changed according to the research study conducted during the course of report completion.

 

 

**Exclusive for Multi-User and Enterprise User.

 

 

 

At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.

Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews  are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.  

Prominent participants in our primary research process include:

  • Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
  • Research and development participants, distributors/suppliers and subject matter experts

Secondary Research includes data extracted from paid data sources:

  • Reuters
  • Factiva
  • Bloomberg
  • One Source
  • Hoovers

Research Methodology

Methodology

Key Inclusions

Methodology

Request A Sample

Ask for Discount

Enquiry Before Buying

Request For Customization

Purchase Options

Buy Now

Reach to us

Call us on

+91-74002-42424

Drop us an email at

sales@absolutemarketsinsights.com